Anticancer agents: Discovery and clinical use
Preprints that describe the discovery of anticancer agents and their clinical use. Includes both small molecules and macromolecules like biologics.
List by Zhang-He Goh
Preprints:
Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer
https://www.biorxiv.org/content/10.1101/512244v1
Malyutina et al. describe an experimental and computational procedure to efficiently predict effective anticancer drug combinations.
Thioridazine as an Anticancer Therapeutic: Interplay with the Isoprenoid Biosynthetic Pathway
https://www.biorxiv.org/content/10.1101/532788v1
Weissenrieder et al. found that while the depletion of isoprenoid pathway intermediates may enhance the sensitivity of glioblastoma multiforme (GBM) cell lines to thioridazine, rescuing the cells with these pathway intermediates did not appear to reverse the toxicity of thioridazine. These findings form in an interesting phenomenon that warrants further investigation in future work; specifically, the authors suggest that this would “clarify the role of the isoprenoid biosynthetic pathway in thioridazine response”.
Discovery of tumoricidal DNA aptamers by effect-directed in-vitro evolution
https://www.biorxiv.org/content/10.1101/629105v1
In their preprint, Mamet et al. describe the use of a platform to identify DNA aptamers with anticancer activity. Significantly, the platform offers researchers the ability to rapidly identify therapeutic aptamers through in vitro evolutionary techniques, a method which could be expanded to include antimicrobial applications.
Anlotinib overcomes multiple drug resistant of the colorectal cancer cells via inactivating PI3K/AKT pathway
https://www.biorxiv.org/content/10.1101/821801v1
Lan et al. describes the mechanisms by which anlotinib, a tyrosine kinase inhibitor, may act against colorectal cancer. In their preprint, the authors tested anlotinib on HCT-8/5-FU and HCT-8 cells, showing that anlotinib 1) inhibited cell viability, 2) inhibited the number of cloned cells, and 3) modulated the expression of various protein associated with apoptosis and metastasis.
A novel HER2-targeted antibody-drug conjugate offers the possibility of clinical dosing at trastuzumab-equivalent exposure levels
https://www.biorxiv.org/content/10.1101/2020.03.13.991448v1
Barfield et al. report the development of CAT-01-106, a trastuzumab-based antibody-drug conjugate. The preprint authors tested CAT-01-106 in preclinical in vivo efficacy and toxicity studies–on mice, rats, and cynomolgus monkeys. The authors’ findings tentatively suggest that CAT-01-106 may exhibit improved pharmacokinetics compared to other existing anti-HER treatments.
CM93, a novel covalent small molecule inhibitor targeting lung cancer with mutant EGFR
https://www.biorxiv.org/content/10.1101/2020.03.09.984500v1
Wang et al. report a 3rd generation tyrosine kinase inhibitor, CM93, that acts against the epidermal growth factor receptor. The authors present positive in vitro and in vivo data: CM93 passed safety screens and exhibited antiproliferative activity in vitro, while also exhibiting good distribution to lungs (the site of action) with a desirable therapeutic window and toxicity profile.
Categories: cancer biology , pharmacology and toxicology
Posted on: 20 May 2019 , updated on: 11 April 2020
(No Ratings Yet)Sign up to customise the site to your preferences and to receive alerts
Register hereAlso in the cancer biology category:
BSCB-Biochemical Society 2024 Cell Migration meeting
This preList features preprints that were discussed and presented during the BSCB-Biochemical Society 2024 Cell Migration meeting in Birmingham, UK in April 2024. Kindly put together by Sara Morais da Silva, Reviews Editor at Journal of Cell Science.
| List by | Reinier Prosee |
CSHL 87th Symposium: Stem Cells
Preprints mentioned by speakers at the #CSHLsymp23
| List by | Alex Eve |
Journal of Cell Science meeting ‘Imaging Cell Dynamics’
This preList highlights the preprints discussed at the JCS meeting 'Imaging Cell Dynamics'. The meeting was held from 14 - 17 May 2023 in Lisbon, Portugal and was organised by Erika Holzbaur, Jennifer Lippincott-Schwartz, Rob Parton and Michael Way.
| List by | Helen Zenner |
CellBio 2022 – An ASCB/EMBO Meeting
This preLists features preprints that were discussed and presented during the CellBio 2022 meeting in Washington, DC in December 2022.
| List by | Nadja Hümpfer et al. |
Fibroblasts
The advances in fibroblast biology preList explores the recent discoveries and preprints of the fibroblast world. Get ready to immerse yourself with this list created for fibroblasts aficionados and lovers, and beyond. Here, my goal is to include preprints of fibroblast biology, heterogeneity, fate, extracellular matrix, behavior, topography, single-cell atlases, spatial transcriptomics, and their matrix!
| List by | Osvaldo Contreras |
Single Cell Biology 2020
A list of preprints mentioned at the Wellcome Genome Campus Single Cell Biology 2020 meeting.
| List by | Alex Eve |
ASCB EMBO Annual Meeting 2019
A collection of preprints presented at the 2019 ASCB EMBO Meeting in Washington, DC (December 7-11)
| List by | Madhuja Samaddar et al. |
Lung Disease and Regeneration
This preprint list compiles highlights from the field of lung biology.
| List by | Rob Hynds |
Biophysical Society Annual Meeting 2019
Few of the preprints that were discussed in the recent BPS annual meeting at Baltimore, USA
| List by | Joseph Jose Thottacherry |
Also in the pharmacology and toxicology category:
FENS 2020
A collection of preprints presented during the virtual meeting of the Federation of European Neuroscience Societies (FENS) in 2020
| List by | Ana Dorrego-Rivas |
COVID-19 / SARS-CoV-2 preprints
List of important preprints dealing with the ongoing coronavirus outbreak. See http://covidpreprints.com for additional resources and timeline, and https://connect.biorxiv.org/relate/content/181 for full list of bioRxiv and medRxiv preprints on this topic
| List by | Dey Lab, Zhang-He Goh |
1
Drug use in special populations
Any drugs that are being used in special populations: Patients with liver and kidney failure, in paediatrics, in geriatrics, and in pregnant or lactating patients. Includes the discovery of factors that could potentially affect drug use in these special populations.
| List by | Zhang-He Goh |
Toxicology of toxicants, existing therapeutics, and investigational drugs
Preprints that describe the toxicology of environmental pollutants and existing and upcoming drugs. Includes both toxicokinetics and toxicodynamics, as well as technological improvements that will help in the characterisation of this field.
| List by | Zhang-He Goh |
Antimicrobials: Discovery, clinical use, and development of resistance
Preprints that describe the discovery of new antimicrobials and any improvements made regarding their clinical use. Includes preprints that detail the factors affecting antimicrobial selection and the development of antimicrobial resistance.
| List by | Zhang-He Goh |
Anticancer agents: Discovery and clinical use
Preprints that describe the discovery of anticancer agents and their clinical use. Includes both small molecules and macromolecules like biologics.
| List by | Zhang-He Goh |
Advances in Drug Delivery
Advances in formulation technology or targeted delivery methods that describe or develop the distribution of small molecules or large macromolecules to specific parts of the body.
| List by | Zhang-He Goh |
Also in the cancer biology category:
Spatial transcriptomics elucidates medulla niche supporting germinal center response in myasthenia gravis thymoma
Invasion of glioma cells through confined space requires membrane tension regulation and mechano-electrical coupling via Plexin-B2
Modeling transcriptional profiles of gene perturbation with a deep neural network
Also in the pharmacology and toxicology category:
Pervasive sublethal effects of agrochemicals as contributing factors to insect decline
Mixed Alkyl/Aryl Phosphonates Identify Metabolic Serine Hydrolases as Antimalarial Targets